Cambridge-based gastrointestinal (GI) molecular diagnostics company Cyted Health has raised $44 million in its Series B funding to expand its operations in the US.
- Established in 2019 by Marcel Gehrung and eight co-founders from the University of Cambridge, Cyted Health develops minimally invasive diagnostics for gastrointestinal diseases.
- The company’s platform includes EndoSign®, a capsule sponge device that safely collects cells from the esophagus, which are then analyzed using advanced molecular biomarker testing to detect pre-cancerous, cancerous, and inflammatory conditions.
- Cyted has completed over 35,000 tests within the UK’s National Health Service, generating a robust portfolio of peer-reviewed research demonstrating high patient acceptability and real-world clinical impact.
- By combining cell collection with biomarker analysis, Cyted detects esophageal disease earlier and more accurately, supporting timely intervention and the expansion of its diagnostic tests through ongoing clinical studies in the US.
Details of the deal
- Cyted Health’s Series B investors include EQT Life Sciences, which funds innovative healthcare companies; Advent Life Sciences, a trans-Atlantic investor building innovative life sciences companies in the UK, Europe, and the US; British Business Bank, Morningside, and BGF.
“Cyted has demonstrated a rare combination of clinical innovation, patient-centered delivery, and commercial execution with an impressive foundation in the UK. We’re proud to support its next phase of growth,” claims Kaasim Mahmood, General Partner at Advent Life Sciences.
- Cyted Health will use the $44 million Series B funding to expand its diagnostics platform in the US and develop new advanced tests for esophageal conditions, building on its proven success in the UK.
- The investment will enhance its EndoSign® device and molecular biomarker testing, strengthen market presence, and support earlier detection of esophageal diseases with innovative, potentially life-saving solutions.
“This investment will help us consolidate our leading position in the market by expanding our US presence and adding new life-saving innovations to our advanced diagnostics portfolio," CEO and co-founder of Cyted Health, Marcel Gehrung, commented.
